// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Cost-Related Medication Nonadherence in Adults with Diabetes Mellitus in the United States

Mohamad Taha - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetes

N/A

Clinical Determinants of Low Attenuation Epicardial Adipose Tissue Volume in Type 2 Diabetes

Sarah L Ayton - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 2 diabetes mellitus

N/A

Bariatric Surgery Reduces the Incidence of Heart Failure in Patients With Obesity

Luke Kostanjsek - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart failure with reduced ejection fraction

N/A

Efficacy and Safety of Inclisiran by Baseline Body Mass Index: A Post Hoc Pooled Analysis of the ORION-9, ORION-10 and ORION-11 Phase III Randomized Controlled Trials

Lawrence A Leiter - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A Shorter Myosin Light Chain Kinase 3 Isoform Maintains Myosin Light Chain 2 Phosphorylation but Does Not Attenuate the Dilated Cardiomyopathy Seen in C57BL/6N Mice

Jack Williams - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Dilated cardiomyopathy

N/A

Biventricular Shape Markers in Repaired Tetralogy of Fallot Associate with Pulmonary Valve Replacement Better Than Standard Clinical Indices

Sachin Govil - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Tetralogy of fallot

N/A

High Prevalence and Significant Impact of Arrhythmias on Healthcare Resource Utilization in Hospitalizations of Patients with Prior (corrected) Congenital Heart/Circulatory Disease

Dipen Zalavadia - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

N/A

Le Coeur En Sabot: Shape and Regional Function Predict Adverse Outcome in Patients with Repaired Tetralogy of Fallot

Anna Mira - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Tetralogy of fallot

N/A

Isosorbide Dinitrate Effect May Improve Exercise Tolerance, Venous Pressure and Liver Stiffness in Patients With Fontan Circulation (The NEET Clinical Trial)

Amee M Bigelow - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Tuberculosis

Isosorbide dinitrate

Prior SARS-CoV-2 Infection is Associated With Subclinical Changes in the Cardiovascular Morphology, Function, Energetics and Exercise Capacity

Rebecca R Chamley - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Dobutamine

Angiotensin-Converting Enzyme 2 (ACE2) is Rate-limiting for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Infection in Beating Stem Cell-Derived Cardiomyocytes

Robyn G Macrae - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Angiotensin II

Impact of Covid-19 on Acute Myocarditis Hospital Admissions in the National Health Service of England, Uk (2019-2020)

Amrit S Lota - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Fulminant myocarditis

N/A

Area Deprivation and COVID-19 Outcomes in Patients With and Without Cardiovascular Disease: The Curator Registry of Houston Methodist

Kobina Hagan - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Worse Outcomes of Out-of-Hospital Cardiac Arrest in COVID-19 versus Non-COVID-19: A Systematic Review and Meta Analysis

Dyutima - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Cardiac arrest

N/A

Renin-Angiotensin-Aldosterone System Inhibition is Associated with Reduced In-Hospital Mortality in Critically Ill Covid-19 Patients with Pre-Existing Hypertension

Kei Sato - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hypertension

Angiotensin II

Etripamil Nasal Spray Reduces Heart Rate in Patients with Paroxysmal Supraventricular Tachycardia Prior to Conversion to Sinus Rhythm

James E Ip - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

Etripamil

Appropriate Therapy in the Subcutaneous and Transvenous ICD: A Secondary Analysis of the PRAETORIAN Trial

Reinoud Knops - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Gender Differences in ICD-Related Complications in the PRAETORIAN Trial

Reinoud Knops - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Personalised Approach is the Key When it Comes to Pacing a Patient with an S-ICD

Mohamed ElRefai - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Effects of Edoxaban on Clinical Outcomes in Extremely Elderly Patients (aged ≥ 90 Years) With Atrial Fibrillation: A Subanalysis of Data from the ELDERCARE-AF Trial

Masaru Kuroda - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

Edoxaban

Copyright © 2026. QuantiNova All rights reserved